Optimal Medical Treatment of Difficult-to-treat Hypertension

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2500 participants.

Also called NCT06275763

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,500 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06275763
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Poland (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06275763. Randomized; triple masking; primary purpose treatment. Start 2023-10-20 (actual); primary completion 2025-12-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Optimal Medical Treatment of Difficult-to-treat Hypertension
Acronym
OPTIMAL-HT
Condition
Hypertension
Intervention (Drug)
Phase C: Eplerenone
Intervention (Drug)
Phase C: Spironolactone
Intervention (Drug)
Phase C: Torasemide
Intervention (Drug)
Phase B: Triplixam / Elestar HCT
Intervention (Diagnostic test)
Phase A: Confirmation of uncontrolled hypertension
Lead sponsor
National Institute of Cardiology, Warsaw, Poland (class: other)

Record details

Record id
cardio:ct-nct06275763
Content hash
8f51490091dfae5a5786e32c14fd7e544e495b3aeb77647ca310fea4e01037e6